Dengue immunization public program in paraná state of Brazil set to achieve WHO 2020 ambition

 News Hour:

Sanofi and its vaccines global business unit Sanofi Pasteur announced that 500,000 doses of Dengvaxia® have been received in Paraná to support a large-scale public dengue immunization program initiated  in the State’s 30 most highly endemic municipalities.

Paraná State, home to 10 million people, has seen a steep 3-fold increase in both dengue incidence and deaths in recent years. In the last year, there have been 55,000 cases reported, costing the State an estimated R$ 330 million (~91 M Euro) in related healthcare expenses.

  Learn about the COVID-19 pandemic from News Hour  

“For the public immunization program being launched today, we have used our extensive dengue surveillance data to ensure that we are targeting people at highest risk of disease. We will vaccinate all individuals 15-27 years of age in 28 municipalities and 9-44 years of age in the two municipalities with the top dengue burden in our State over the next three weeks,” said Michele Caputo Neto, Paraná Health Secretary.

“Paraná has a good track record in vaccination coverage in general and successful implementation of this dengue immunization strategy could result in 74% reduction in disease burden in these highly impacted municipalities within 5 years, according to a dengue vaccine impact study published in the Brazilian Journal of Health Economics,” Secretary Neto noted.

Dr. Stephen J. Thomas, a physician-scientist at the Walter Reed Army Institute of Research in Silver Spring, Maryland who is an international dengue expert commented on the public immunization program initiated by Paraná State today. “Dengue remains one of the world’s most important mosquito transmitted diseases causing significant human suffering and financial cost. The strategic deployment of a safe and effective dengue vaccine offers the best hope of reducing dengue’s burden, especially in highly endemic countries like Brazil.”

Dengvaxia’s safety and efficacy have been documented in a large clinical study program involving more than 40,000 people in studies conducted in 15 countries around the world including Brazil which participated in both phases II and III of the clinical development of the vaccine. The safety, efficacy and public health value of the dengue vaccine has been independently endorsed by the World Health Organization (WHO) in position paper onDengvaxia published on 29th July 2016, which is consistent with the earlier positive recommendation on the dengue vaccine issued by the WHO’s Strategic Advisory Group of Experts on Immunization last April.

Guillaume Leroy, of Sanofi Pasteur, added “Introduction of the dengue vaccine first in endemic countries like Brazil has always been Sanofi Pasteur’s priority because this is where the vaccine can have the greatest impact on disease burden globally. Furthermore, successful implementation of Dengvaxia in a large-scale public program in Paraná will serve as a benchmark for dengue prevention efforts elsewhere in the country and in the world.”

Sanofi Pasteur will continue to address all supply demands coming from all clinics in Brazil, both public and private, as well as any additional requests from other countries supported by company’s ample dengue vaccine supply capacity from its production facility in France.

Follow News Hour
Rafiuzzaman Sifat

Md. Rafiuzzaman Sifat, a CSE graduate turned into journalist, works at News Hour as a staff reporter. He has many years of experience in featured writing in different Bangladeshi newspapers. He is an active blogger, story writer and social network activist. He published a book named 'Se Amar Gopon' inEkushe boi mela Dhaka 2016. Sifat got a BSc. from Ahsanullah University of Science & Technology, Bangladesh. He also works as an Engineer at Bangla Trac Communications Ltd. As an avid traveler and a gourmet food aficionado, he is active in publishing restaurant reviews and cutting-edge articles about culinary culture.
No Comments
Scroll Up
%d bloggers like this: